Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...
Zacks Investment Research on MSN1d
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should KnowShares of Pliant Therapeutics PLRX have plunged 88.5% in the past three months following recent setbacks in the clinical ...
Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...
Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback